Lv7
3370 积分 2022-08-26 加入
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study
5小时前
待确认
DLBCL: Who is high risk and how should treatment be optimized?
6小时前
待确认
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
13小时前
待确认
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
13小时前
待确认
DLBCL: Who is high risk and how should treatment be optimized?
3天前
已完结
Long-term outcomes following CAR T cell therapy: what we know so far
4天前
已完结
Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas
5天前
已完结
53P Distinct cellular and molecular patterns in pre-treatment peripheral blood are associated with CAR-T outcomes in diffuse large B-cell lymphoma
5天前
已完结
Anti-CD19 CAR T-cell therapy for primary and secondary CNS lymphomas
5天前
已完结
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
6天前
已完结
皖公网安备34019202002308
